InteRNA Technologies Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Employees
  • 15
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $22.4M
Latest Deal Amount
  • Investors
  • 7

InteRNA Technologies General Information

Description

Developer of a pipeline of proprietary RNA therapeutics intended for cancer treatment. The company's proprietary preclinical miRNA drug candidates target key processes in cancer initiation and progression and address the high unmet medical need for novel therapeutics, enabling patients to get improved efficacy and be less prone to drug-acquired resistance.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Nijmegen City Centre
  • Jonkerbosplein 52
  • 6534 Nijmegen
  • Netherlands
+31 024 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

InteRNA Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 09-Feb-2021 $22.4M 000.00 Completed Product Development
7. Later Stage VC 01-Jan-2018 000.00 Completed Product Development
6. Grant 12-Dec-2016 000.00 000.00 Completed Product Development
5. Later Stage VC (Series A) 29-Oct-2015 000.00 000.00 Completed Product Development
4. Later Stage VC 26-Mar-2013 00.000 Completed Product Development
3. Grant 00.000 Completed Startup
2. Grant 16-Nov-2010 $1.8M $1.94M Completed Startup
1. Seed Round 01-Dec-2006 $1.94M $1.94M Completed Startup
To view InteRNA Technologies’s complete valuation and funding history, request access »

InteRNA Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a pipeline of proprietary RNA therapeutics intended for cancer treatment. The company's proprietary preclin
Drug Discovery
Nijmegen, Netherlands
15 As of 2021
000.00
00000000000 000.00

0000000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
000000000000000
Hannover, Germany
00 As of 0000
00000
00000000000 00000

0000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, s
0000 000000000
San Diego, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InteRNA Technologies Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cardior Venture Capital-Backed Hannover, Germany 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

InteRNA Technologies Patents

InteRNA Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3752164-A1 Anticancer microrna and lipid formulations thereof Pending 12-Feb-2018 0000000000
AU-2019218557-A1 Anticancer microrna and lipid formulations thereof Pending 12-Feb-2018 0000000000
CA-3088321-A1 Anticancer microrna and lipid formulations thereof Pending 12-Feb-2018 0000000000
JP-2021513508-A Anti-cancer microrna and its lipid preparation Pending 12-Feb-2018 0000000000
US-20210038732-A1 Anticancer microrna and lipid formulations thereof Pending 12-Feb-2018 A61K47/542
To view InteRNA Technologies’s complete patent history, request access »

InteRNA Technologies Executive Team (8)

Name Title Board Seat Contact Info
Roel Schaapveld Ph.D Chief Executive Officer
Laurens van Pinxteren Chief Operating Officer
Michel Janicot Ph.D Acting Chief Development Officer
You’re viewing 3 of 8 executive team members. Get the full list »

InteRNA Technologies Board Members (12)

Name Representing Role Since
Andrea Van Elsas Ph.D Self Supervisory Board Member 000 0000
Brian Bronk Ph.D Self Supervisory Board Member 000 0000
Gabriele Campi Self Board Member 000 0000
Hans Schikan Self Chairman of Supervisory Board 000 0000
Karl Rothweiler Aglaia Oncology Funds Supervisory Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

InteRNA Technologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InteRNA Technologies Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AurorA Science Corporation Minority 000 0000 000000 0
BioX Biosciences Corporation Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Inkef Capital Venture Capital Minority 000 0000 000000 0
KU Leuven Research & Development Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »